Chemical: Drug
gemtuzumab ozogamicin

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for gemtuzumab ozogamicin

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs11231825 NC_000011.10:g.64592802T>C, NC_000011.9:g.64360274T>C, NG_008110.1:g.6993T>C, NM_001276326.1:c.426T>C, NM_001276327.1:c.426T>C, NM_144585.3:c.426T>C, NM_153378.2:c.-83T>C, NP_001263255.1:p.His142=, NP_001263256.1:p.His142=, NP_653186.2:p.His142=, XM_005273740.1:c.426T>C, XM_005273741.1:c.426T>C, XM_005273742.1:c.426T>C, XM_005273743.1:c.426T>C, XM_005273744.1:c.426T>C, XM_005273745.1:c.426T>C, XM_005273746.1:c.426T>C, XM_005273747.1:c.-764T>C, XM_006718430.2:c.426T>C, XM_006718431.2:c.321T>C, XP_005273797.1:p.His142=, XP_005273798.1:p.His142=, XP_005273799.1:p.His142=, XP_005273800.1:p.His142=, XP_005273801.1:p.His142=, XP_005273802.1:p.His142=, XP_005273803.1:p.His142=, XP_006718493.1:p.His142=, XP_006718494.1:p.His107=, rs17846504, rs17859573, rs60376821
T > C
SNP
H142H
No VIP available No Clinical Annotations available VA
rs1826909 NC_000004.11:g.100217743C>T, NC_000004.12:g.99296586C>T, NR_037884.1:n.4161-3713C>T, rs17512416, rs4525982, rs61683245
C > T
SNP
No VIP available CA VA
rs2070673 NC_000010.10:g.135340567A>T, NC_000010.11:g.133527063A>T, NG_008383.1:g.4701A>T, NM_000773.3:c.-333A>T, XM_005252665.1:c.21+190A>T
A > T
SNP
No VIP available CA VA
rs2302948 NC_000019.10:g.48592808C>T, NC_000019.9:g.49096065C>T, NG_029063.1:g.45637C>T, NM_004605.2:c.592C>T, NM_177973.1:c.637C>T, NP_004596.2:p.Leu198=, NP_814444.1:p.Leu213=, XM_005259182.1:c.205C>T, XM_005259182.2:c.205C>T, XP_005259239.1:p.Leu69=, rs59383755
C > T
SNP
L198L
No VIP available CA VA
rs2515641 NC_000010.10:g.135351362T>C, NC_000010.11:g.133537858C>T, NG_008383.1:g.15496C=, NG_008383.1:g.15496C>T, NM_000773.3:c.1263C=, NM_000773.3:c.1263C>T, NP_000764.1:p.Phe421=, XM_005252665.1:c.1323T>C, XP_005252722.1:p.Phe441=, rs17012766, rs60244712
T > T
SNP
F421F
No VIP available CA VA
rs4149056 NC_000012.11:g.21331549T>C, NC_000012.12:g.21178615T>C, NG_011745.1:g.52422T>C, NM_006446.4:c.521T>C, NP_006437.3:p.Val174Ala, rs52816141, rs60037639
T > C
SNP
V174A
No VIP available No Clinical Annotations available VA
rs6811453 NC_000004.11:g.100194977G>A, NC_000004.12:g.99273820G>A, NR_037884.1:n.3790-12975G>A, XR_244675.1:n.691-305G>A
G > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Mylotarg
  • anti-CD33
  • gemtuzumab ozogamicin
Trade Names
  • Mylotarg (Wyeth)
Brand Mixture Names

PharmGKB Accession Id

PA164749431

Type(s):

Drug

Description

Recombinant humanized IgG4, kappa antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin, isolated from fermentation of a bacterium, Micromonospora echinospora ssp. calichensis. The antibody portion of Mylotarg binds specifically to the CD33 antigen, The anti-CD33 hP67.6 antibody is produced by mammalian cell suspension culture using a myeloma NS0 cell line.

Source: Drug Bank

Indication

For treatment of CD33-positive acute myeloid leukemia in patients 60 and over who are not candidates for other chemotherapy.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in DNA double strand breaks and cell death.

Source: Drug Bank

Pharmacology

Used for the treatment of acute myeloid leukemia (AML), mylotarg binds to the CD33 antigen, which is expressed on the surface of leukemic cells in more than 80% of patients with AML. The CD33 antigen is not expressed on pluripotent hematopoietic stem cells or nonhematopoietic cells. This gives mylotarg the selectivity needed to target leukemic cells.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Most likely removed by opsonization via the reticuloendothelial system.

Source: Drug Bank

Toxicity

The most frequently reported toxicities are myelosuppression and hepatic veno-occlusive disorder.

Source: Drug Bank

Chemical Properties

Canonical SMILES

Not Available

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
C1QA (source: Drug Bank)
C1QB (source: Drug Bank)
C1QC (source: Drug Bank)
C1R (source: Drug Bank)
C1S (source: Drug Bank)
CD33 (source: Drug Bank)
FCGR1A (source: Drug Bank)
FCGR2A (source: Drug Bank)
FCGR2B (source: Drug Bank)
FCGR2C (source: Drug Bank)
FCGR3A (source: Drug Bank)
FCGR3B (source: Drug Bank)

Curated Information ?

EvidenceDrug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
gemtuzumab ozogamicin

Curated Information ?

Publications related to gemtuzumab ozogamicin: 2

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. The pharmacogenomics journal. 2012. Iacobucci I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0008-4510-01
DrugBank:
DB00056
Therapeutic Targets Database:
DAP000390
FDA Drug Label at DailyMed:
32fd2bb2-1cfa-4250-feb8-d7956c794e05

Clinical Trials

These are trials that mention gemtuzumab ozogamicin and are related to either pharmacogenetics or pharmacogenomics.

No trials found.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.